US FDA overhauls regulatory office
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration revealed it has reorganised its Office of Regulatory Affairs, a move the agency described as a "positive step forward" to better position it to meet the demands of the rapid modernisation and globalisation of the products it regulates and the new legislative authorities provided by Congress, along with better protecting public health.